search
Back to results

Fitmore Versus CLS Stem in Total Hip Arthroplasty. Bilateral One-stage Operations

Primary Purpose

Primary Hip Osteoarthritis, Secondary Hip Osteoarthritis Due to Idiopathic Femoral Head Necrosis, Childhood or Inflammatory Disease, Bilateral Hip Disease

Status
Active
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Total hip arthroplasty (Fitmore or CLS uncemented femoral stem made by Zimmer-Biomet, Warshaw, USA)
Sponsored by
Sahlgrenska University Hospital, Sweden
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Primary Hip Osteoarthritis focused on measuring Hip, Arthroplasty, Stem, Outcome

Eligibility Criteria

35 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Hip anatomy suitable for the Fitmore stem according to preoperative planning
  2. Males and females aged 35 to 75 years (with bilateral hip disease).
  3. Primary osteoarthritis.
  4. Secondary osteoarthritis due to idiopathic femoral head necrosis, childhood or inflammatory disease. -

Exclusion Criteria:

  1. Treatment with Cortisol or known osteoporosis.
  2. Low expected activity rate due to other diseases including any generalized joint disease.
  3. Anatomy unsuitable for the Fitmore stem.

Sites / Locations

    Outcomes

    Primary Outcome Measures

    Preferred hip (the hip arthroplasty preferred by the patient, right or left side)
    Study specific protocol in which the patient from a general view tics one of 3 options: left side, right side or no difference). In the term preferred view the patient is asked to consider all aspects they Think are important such as freedom from pain, mobility, function or any other type of discomfort.

    Secondary Outcome Measures

    Stem subsidence (distal migration of the stem)
    Stem subsidence in mm (distal migration of the femoral head center) measured with radiostereometry
    Extent of radiolucent lines around the stem
    Development of radiolucent lines in percent of total stem circumference as measured on conventional radiographs
    Any new surgical procedure where the stem is removed or Exchanges (revision of the stem)
    Stem Exchange or removal due to loosening, dislocation or periprostheic fracture

    Full Information

    First Posted
    March 7, 2017
    Last Updated
    April 7, 2017
    Sponsor
    Sahlgrenska University Hospital, Sweden
    Collaborators
    Zimmer Biomet
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03112785
    Brief Title
    Fitmore Versus CLS Stem in Total Hip Arthroplasty. Bilateral One-stage Operations
    Official Title
    Randomized Comparison Between the Fitmore and the CLS Stem in Patients Operated in One-stage Due to Bilateral Symptomatous Hip Disease
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    April 2017
    Overall Recruitment Status
    Active, not recruiting
    Study Start Date
    March 17, 2011 (Actual)
    Primary Completion Date
    June 2026 (Anticipated)
    Study Completion Date
    June 2026 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Sahlgrenska University Hospital, Sweden
    Collaborators
    Zimmer Biomet

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Main question: Will use of a stem design that allows anatomical reconstruction of the hip joint improve the outcome in terms of hip function and patient satisfaction without causing any adverse effects? Background: Total hip arthroplasty with use of the most well documented implants is a safe and cost-effective procedure. In the Swedish Hip Arthroplasty register the CLS stem has a 16 years implant survival of 97, 5 %. It is a classic design which requires resection of most of the neck. The stem also intrudes into the greater trochanter which in patients with certain types of proximal hip anatomy makes proper introduction of the stem difficult. Finally it has a standard stem length which will jeopardise future stem removal should there occur any late infection or instability problems. Short uncemented stems have been introduced to enable a more anatomic reconstruction of the hip joint and to cause less invasion of the femoral canal to facilitate future revision should it be necessary. A more conservative resection of neck could also be of value to improve the clinical outcome by improved hip function and patient satisfaction. Purpose of the present study and design: In a prospective study the clinical outcome, stem fixation and bone remodelling around a short stem (Fitmore) will be studied. The main focus will be to evaluate patient reported outcomes especially concerning function, over all satisfaction, pain and activity. All patients will receive the same cup (Trilogy). This cup is chosen because it has a very thorough documentation in prospective RSA studies and in the Swedish hip arthroplasty register. All cups will be supplied with insert made of high molecular polyethylene (Longevity). Number of hips in the study: 44 consecutive cases
    Detailed Description
    Main question: Will use of a stem design that allows anatomical reconstruction of the hip joint improve the outcome in terms of hip function and patient satisfaction without causing any adverse effects? Background: Total hip arthroplasty with use of the most well documented implants is a safe and cost-effective procedure. In the Swedish Hip Arthroplasty register the CLS stem has a 16 years implant survival of 97, 5 %. It is a classic design which requires resection of most of the neck. The stem also intrudes into the greater trochanter which in patients with certain types of proximal hip anatomy makes proper introduction of the stem difficult. Finally it has a standard stem length which will jeopardise future stem removal should there occur any late infection or instability problems. Short uncemented stems have been introduced to enable a more anatomic reconstruction of the hip joint and to cause less invasion of the femoral canal to facilitate future revision should it be necessary. A more conservative resection of neck could also be of value to improve the clinical outcome by improved hip function and patient satisfaction. Purpose of the present study and design: In a prospective study the clinical outcome, stem fixation and bone remodelling around a short stem (Fitmore) will be studied. The main focus will be to evaluate patient reported outcomes especially concerning function, over all satisfaction, pain and activity. All patients will receive the same cup (Trilogy). This cup is chosen because it has a very thorough documentation in prospective RSA studies and in the Swedish hip arthroplasty register. All cups will be supplied with insert made of high molecular polyethylene (Longevity). Number of hips in the study: 44 consecutive cases Methods: EQ-5D including VAS-scale to evaluate pain and over all satisfaction, (specific questionnaire concerning side preference), Harris Hip Score, DXA, radiostereometry and gait analysis. A. Clinical parameters: EQ-5D form (including VAS for pain and satisfaction) is filled in by the patients. Harris Hip Score is filled in by the examiner. SF-36 and activity scale (UCLA) is filled in by the patient. Patients also fill in a study specific form including questions about hip preferred and a pain drawing. Clinical parameters will be studied preoperative after 1, 2, 5, 7 and 10 years. B. Conventional radiography: Examinations will be done preoperatively, postoperatively, after 1, 2, 5, 7 and 10 years. C. Computed tomography: Preoperatively, after 1 and 7 years. D. DXA measurements: Postoperatively, after 6 months, 1, 2, 5, 7 and 10 years. E. Radiostereometry: Postoperatively, after 3 and 6 months, 1, 2, 5, 7 and 10 years. F. Gait analysis: 1 and 2 years. Focus of interest: A. Patient reported outcomes and especially Oxford Hip Score will constitute our primary outcome parameter. B. Conventional radiography (preop with metallic indicator to determine magnification) will include AP, True lateral and pelvic view. C. Computed Tomography will be done for preoperative planning in 3D (a new software has been developed). Preoperative planning in 3D will be done for booth types of prostheses. A prerequisite is that we have 3D-models available for all implants used in the study. Preoperative planning will also be done in 2D. The CT-examinations will be also used to measure the anteversion of the femur (preoperatively) and of the femoral component (1 year exam). The influence of this parameter on clinical results and fixation will be studied. CT at 7 years will be compared with previous examinations to study development of any osteolysis. D. DXA - studies will be done to study bone remodelling in terms of changes of bone mineral density around the implant. Both the femoral- and the acetabular side will be studied. E. Radiostereometry. The cup will be marked during surgery. Model based RSA for the cup Component will also be used. On the femoral side the femoral head centre will be used to measure stem migration. Tantalum markers will be inserted into the acetabular bone and proximal femur. Femoral component migration will be measured as translations of the femoral head centre in three directions (medial/lateral, proximal/distal, anterior/posterior). Implant migration between the 6 months and 1 year follow up will constitute our second outcome parameter. Comments: From previous studies of uncemented stems it has been found that these implants often subside up to 1-2 mm and some even more during 6 months (rarely up to 1 year) and may thereafter become stable and at least according to conventional radiography achieve osseous fixation. Two years after the operation patients will also be studied using dynamic RSA during active abduction and flexion. The aim is to study any-lift off during these motions. A new radiostereometric laboratory has been installed in 2010 which has facilitated these types of examinations. In addition the fixation of the cup and wear (femoral head penetration) will be measured. F. Gait analysis will be performed one and two years after the operation. The patients will be studied walking and when rising from a chair. This analysis will focus on flexion/extension, motions of the hip and the knee and the ground reacting forces. The ab/adduction movements over the hip during walking will also be recorded.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Primary Hip Osteoarthritis, Secondary Hip Osteoarthritis Due to Idiopathic Femoral Head Necrosis, Childhood or Inflammatory Disease, Bilateral Hip Disease, Surgical Treatment
    Keywords
    Hip, Arthroplasty, Stem, Outcome

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Model Description
    Patients with bilateral degenerative hip osteoarthritis are operated with a short stem total hip arthroplasty on one side and a conventional stem on the opposite side. Implant selection is randomised on the most symptomatic side, the second side receives the type of stem not used on the first one.
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    44 (Actual)

    8. Arms, Groups, and Interventions

    Intervention Type
    Device
    Intervention Name(s)
    Total hip arthroplasty (Fitmore or CLS uncemented femoral stem made by Zimmer-Biomet, Warshaw, USA)
    Intervention Description
    The most symptomatic side is randomised to one of the two stem types studied. If the patient has equal amount of symptoms on both sides, the one with most pronounced degenerative Changes on plain radiographs will be randomised. On the second side the type of stem not used on the first one will be inserted. All patients and allhip will receive the same type and design of cup.
    Primary Outcome Measure Information:
    Title
    Preferred hip (the hip arthroplasty preferred by the patient, right or left side)
    Description
    Study specific protocol in which the patient from a general view tics one of 3 options: left side, right side or no difference). In the term preferred view the patient is asked to consider all aspects they Think are important such as freedom from pain, mobility, function or any other type of discomfort.
    Time Frame
    2 years
    Secondary Outcome Measure Information:
    Title
    Stem subsidence (distal migration of the stem)
    Description
    Stem subsidence in mm (distal migration of the femoral head center) measured with radiostereometry
    Time Frame
    2 years
    Title
    Extent of radiolucent lines around the stem
    Description
    Development of radiolucent lines in percent of total stem circumference as measured on conventional radiographs
    Time Frame
    2 years
    Title
    Any new surgical procedure where the stem is removed or Exchanges (revision of the stem)
    Description
    Stem Exchange or removal due to loosening, dislocation or periprostheic fracture
    Time Frame
    2, 5 and 10 years

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    35 Years
    Maximum Age & Unit of Time
    75 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Hip anatomy suitable for the Fitmore stem according to preoperative planning Males and females aged 35 to 75 years (with bilateral hip disease). Primary osteoarthritis. Secondary osteoarthritis due to idiopathic femoral head necrosis, childhood or inflammatory disease. - Exclusion Criteria: Treatment with Cortisol or known osteoporosis. Low expected activity rate due to other diseases including any generalized joint disease. Anatomy unsuitable for the Fitmore stem.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Johan N Kärrholm, MD, Professor
    Organizational Affiliation
    Sahlgrenska University Hospital, Sweden
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Fitmore Versus CLS Stem in Total Hip Arthroplasty. Bilateral One-stage Operations

    We'll reach out to this number within 24 hrs